摘要
目的系统评价匹多奠德预防儿童急性呼吸道感染的临床疗效及安全性，为其临床防治提供循证参考。方法用计算机检索PubMed、Cochrane图书馆、EMbase（Ovid）、CNKI、CBM、万方及维普数据库，收集与匹多莫德预防儿童急性呼吸道感染相关的随机对照试验（RCT），检索截止时间为2017年2月，并对纳入研究进行资料提取、质量评价及Meta分析。结果共纳入RCT10项，合计1708例患儿；匹多莫德组随访2个月时急性呼吸道感染的发生率、随访3个月时急性呼吸道感染的发生率、随访1个月时发热的发生率、随访2个月时发热的发生率均低于对照组的；随访1个月时，匹多莫德组急性呼吸道感染的发生率、不良反应及并发症的发生率与对照组的比较无统计学意义。结论当前文献显示：匹多莫德可显著降低儿童急性呼吸道感染和发热的发生率，不良反应及并发症的发生率低，未观测到严重不良反应的发生。
OBJECTIVE To systematically evaluation the efficacy and safety of Pidotimod in the treatment of acute respiratory infection in children, and to provide the evidence - based reference for clinical treatment. METHODS Databases including Pubmed, the Cochrane library, EMbase （Ovid） , CNKI, CBM, WanFang Database and VIP were searched to collect randomized controlled trials （RCTs） about pidotimod in the treatment of acute respiratory infection in children,the search deadline was February 2017. Data extrac- tion, quality evaluation and Meta - analysis were performed. RESULTS 10 RCTs involving 1708 children were included. Compared with the control group, the Pidotimod group had better curative effect of the incidence of respiratory tract infection followed up for 2 months,the incidence of respiratory tract infection followed up for 3 months, the incidence of fever followed up for 1 months and the incidence of fever followed up for 2 months, but there were no significant differences between the Pidotimod group and the control group in the incidence of respiratory tract infection followed up for 1 months and the incidence of adverse reaction and complications. CONCLUSION Pidotimod could significantly reduce the incidence of respiratory tract,infection and the incidence of fever, the inci- dence of adverse reaction and complications were low and symptoms were mild.
作者
李汶睿
黄亮
胡志强
陈莉娜
曾力楠
蒋璐灿
张伶俐
王凌
LI Wenrui;HUANG Liang;HU Zhiqiang;CHEN Lina;ZENG Linan;JIANG Lucan;ZHANG Lingli;WANG Ling(West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, 610041 P. R. China;Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu , Sichuan , 610041 P. R. China;Evidence - Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041 P, R. China;Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu , Sichuan , 610041 P. R. China)
出处
《华西药学杂志》
CAS
CSCD
2018年第3期319-322,共4页
West China Journal of Pharmaceutical Sciences
基金
国家自然科学基金资助项目(批准号:81373381)
